Treatment received in 2 groups of HIV–associated aggressive B lymphomas with or without MYC rearrangement
| . | Patients with MYC+ n = 43 . | Patients with MYC– n = 112 . | Total N = 155 . | P value . |
|---|---|---|---|---|
| Rituximab | 41 (95%) | 99 (88%) | 140 (90%) | ns |
| CHOP/CHOP-like | 15 (35%) | 76 (68%) | 91 (59%) | .0001 |
| Infusional therapy | 8 (19%) | 9 (8%) | 17 (11%) | .063 |
| DA-EPOCH | 6 | 6 | 12 | |
| CDE | 2 | 3 | 5 | |
| iCT | 19 (44%) | 23 (20%) | 42 (27%) | .003 |
| CARMEN Regimen28 | 9 | 1 | 10 | |
| GMALL | 3 | 2 | 5 | |
| CODOX IVAC | 2 | 1 | 3 | |
| CT∗ + ASCT consolidation | 3 | 15 | 18 | |
| Other† | 2 | 4 | 6 | |
| Palliative care | 1 (2%) | 4 (3%) | 5 (3%) | ns |
| CNS prophylaxis | 32/37‡ (86%) | 62/94‡ (66%) | 94/131‡ (72%) | .011 |
| IT (MTX ± ARA-C) | 24 | 55 | 79 | |
| Iv MTX ± IT | 8 | 7 | 15 | |
| Radiotherapy | 2 (5%) | 9 (8%) | 11 (7%) | ns |
| . | Patients with MYC+ n = 43 . | Patients with MYC– n = 112 . | Total N = 155 . | P value . |
|---|---|---|---|---|
| Rituximab | 41 (95%) | 99 (88%) | 140 (90%) | ns |
| CHOP/CHOP-like | 15 (35%) | 76 (68%) | 91 (59%) | .0001 |
| Infusional therapy | 8 (19%) | 9 (8%) | 17 (11%) | .063 |
| DA-EPOCH | 6 | 6 | 12 | |
| CDE | 2 | 3 | 5 | |
| iCT | 19 (44%) | 23 (20%) | 42 (27%) | .003 |
| CARMEN Regimen28 | 9 | 1 | 10 | |
| GMALL | 3 | 2 | 5 | |
| CODOX IVAC | 2 | 1 | 3 | |
| CT∗ + ASCT consolidation | 3 | 15 | 18 | |
| Other† | 2 | 4 | 6 | |
| Palliative care | 1 (2%) | 4 (3%) | 5 (3%) | ns |
| CNS prophylaxis | 32/37‡ (86%) | 62/94‡ (66%) | 94/131‡ (72%) | .011 |
| IT (MTX ± ARA-C) | 24 | 55 | 79 | |
| Iv MTX ± IT | 8 | 7 | 15 | |
| Radiotherapy | 2 (5%) | 9 (8%) | 11 (7%) | ns |